MUC5AC NPC-1 Peptidomimetics for Cancer Detection and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early detection and treatment of cancers such as colorectal and pancreatic cancer are limited, and there is a need for new diagnostic and therapeutic compositions targeting MUC5AC expression in these cancers.
Innovation Solution
Development of peptidomimetics derived from the NPC-1 epitope of MUC5AC, including polypeptides, fusion proteins, and conjugates that can be used in diagnostic and therapeutic compositions, as well as methods for their manufacture and use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and therapeutic methods are used for colorectal and pancreatic cancer, then treatment options are available, but early detection and treatment effectiveness are limited
Solution Approach 1:
The patent segments the MUC5AC mucin protein into specific peptide epitopes (such as the NPC-1 epitope) that are differentially expressed in cancer cells. By targeting these segmented epitopes rather than the entire protein, the diagnostic and therapeutic compositions achieve higher early detection effectiveness while maintaining manageable complexity through focused molecular targeting.
Solution Approach 2:
The patent applies local quality by creating compositions that specifically target the NPC-1 epitope region of MUC5AC, which is aberrantly expressed in colorectal and pancreatic cancers but not in normal tissues. This localized molecular targeting enhances diagnostic reliability and therapeutic effectiveness without requiring complex multi-target systems.
2Reliability
If peptidomimetics targeting MUC5AC are developed, then diagnostic and therapeutic effectiveness improve, but composition complexity increases
Solution Approach 1:
The patent uses peptidomimetics that copy or mimic the three-dimensional structure and binding properties of the native NPC-1 epitope from MUC5AC. These peptidomimetic copies can be synthesized with precise control over their structure-activity relationship, improving detection and treatment effectiveness while allowing optimization of chemical simplicity and stability compared to full-length protein constructs.
Solution Approach 2:
The patent employs parameter changes by modifying amino acid residues in the peptide sequence to create peptidomimetics with enhanced stability, affinity, and selectivity for the MUC5AC NPC-1 epitope. By systematically varying parameters such as amino acid composition, peptide length, and structural constraints, the compositions achieve superior cancer targeting effectiveness with optimized complexity.
Data Source
AI summary
The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.